[Variation of female migraine after menopause and its prophylaxis and treatment].
320 cases of female migraine after menopause according to the diagnostic criteria were studied by using 1:1 matched analysis. It was found that the additional symptoms increased after menopause. Eighty cases available for follow-up were divided into two groups, on which the treatment tests were done. Each patient in group I took Nilestrioli 2 mg twice a month and Perphenazine 12 mg and Doxepin 75 mg per day, while each patient in group II took Tolfenamic acid 300 mg a day. Two months after treatment, the cure rates were 57.58% in group I and 27.78% in group II. Two monthes after the cessation of therapy, 2 cases had relapses in group I. These data indicate that the decrease of estrin disorder and the additional symptoms after monopause play important roles in the change of migraine physiology, and the corresponding treatment methods are rational.
Guo
S
S
Department of Neurology, Jinan Military General Hospital.
Chen
C
C
Xue
G
G
D000700:Analgesics / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D004316:Doxepin / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy* / Q000517:prevention & control*; D010546:Perphenazine / Q000627:therapeutic use; D017698:Postmenopause; D011800:Quinestrol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
D000700:Analgesics; D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D045166:Estradiol Congeners; D062367:ortho-Aminobenzoates; D004316:Doxepin; C009500:tolfenamic acid; C010722:nylestriol; D010546:Perphenazine; D011800:Quinestrol